<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100926004819N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-01-27</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparative investigation of two sedation methods during cataract surgery with two combinations of sodium thiopental and ketamine vs propofol and ketamine under local anesthesia.</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study of two sedation methods during cataract surgery with two combinations of sodium thiopental and ketamine vs propofol and ketamine under local anesthesia in 60 patients who are candidates for cataract surgery due to old age and the effectiveness and side effects of this combination</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-01-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/68177</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Randomization is done by simple randomization method. The randomization unit is individual and layered randomization is not used. The randomization tool is Randomize Allocation software, Blinding description: In this study, one group of patients received ketamine and propofol, and the other group received ketamine and sodium thiopental. The study is triple-blind, which means the patient does not know about his group, the person who collects the data does not know which patient received which combination, and the statistical analyst does not know about the groups either.</study_design>
      <phase>2</phase>
      <hc_freetext>senile cataract.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first group, after placing the patient on the surgical bed, ambulatory monitoring of blood pressure, ECG, pulse oximetry and capnograph is established for monitoring the patient during the operation. Systolic and diastolic blood pressure, arterial blood oxygen saturation, end-expiratory CO2 and heart rate are measured and recorded. Then, to start sedation, the combination of fentanyl with a dose of 1µ/Kg, propofol with a dose of 2mg/kg/lit and ketamine with a dose of 0.3mg/kg will be used, then during surgery to maintain sedation with ketamine with a dose of 0.3mg/kg every five minutes and Thiopental sodium is found at a dose of 0.3 mg/kg every five minutes. Intervention 2: Intervention group: The second group, after placing the patient on the surgical bed, ambulatory monitoring of blood pressure, ECG, pulse oximetry and capnograph is established for monitoring the patient during the operation. Systolic and diastolic blood pressure, arterial blood oxygen saturation, end-expiratory CO2 and heart rate are measured and recorded. Then, to start sedation, fentanyl with a dose of 1µ/Kg, propofol with a dose of 2mg/kg/lit, and ketamine with a dose of 0.3mg/kg will be used, then during surgery to maintain sedation with a combination of ketamine with a dose of 0.3mg/kg every five minutes. and propofol at a dose of 2 mg/kg every five minutes.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of the data, such as the information related to the main result or the like, can be shared.

When:
The access period starts 12 months after the publication of the results

To whom:
Researchers working in academic institutions

Conditions:
If used for other studies

Where to obtain:
If you request access to the documents, send a message to the email below.
fatemeh .sadat075@gmail.com

How to obtain:
Approval of Research Committee and Ethics Committee of Isfahan University of Medical Sciences

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Saied Morteza Heidari Tabaei Zavareh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan Province, Isfahan, Qods Square, Ayat A... Modares St., No. 1</address>
        <city>isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۷۴۶۷۳۴۶۱</zip>
        <telephone>+98 921 114 5026</telephone>
        <email>fatemeh.sadat075@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Saied Morteza Heidari Tabaei Zavareh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Isfahan Province, Isfahan, Qods Square, Ayat A... Modares St., No. 1</address>
        <city>isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۱۷۴۶۷۳۴۶۱</zip>
        <telephone>+98 921 114 5026</telephone>
        <email>fatemeh.sadat075@gmail.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Candidate patients for cataract surgery due to old age
Consent to participate in the study
Age between 30 and 70 years
ASA1/2/3</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Need general anesthesia
Seizures and response to study drugs
High risk of surgery such as monocular or traumatic patients
History of alcoholism, smoking, drugs</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T88.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other complications of anesthesia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group, after placing the patient on the surgical bed, ambulatory monitoring of blood pressure, ECG, pulse oximetry and capnograph is established for monitoring the patient during the operation. Systolic and diastolic blood pressure, arterial blood oxygen saturation, end-expiratory CO2 and heart rate are measured and recorded. Then, to start sedation, the combination of fentanyl with a dose of 1µ/Kg, propofol with a dose of 2mg/kg/lit and ketamine with a dose of 0.3mg/kg will be used, then during surgery to maintain sedation with ketamine with a dose of 0.3mg/kg every five minutes and Thiopental sodium is found at a dose of 0.3 mg/kg every five minutes.</i_keyword>
      <i_keyword>Intervention group: The second group, after placing the patient on the surgical bed, ambulatory monitoring of blood pressure, ECG, pulse oximetry and capnograph is established for monitoring the patient during the operation. Systolic and diastolic blood pressure, arterial blood oxygen saturation, end-expiratory CO2 and heart rate are measured and recorded. Then, to start sedation, fentanyl with a dose of 1µ/Kg, propofol with a dose of 2mg/kg/lit, and ketamine with a dose of 0.3mg/kg will be used, then during surgery to maintain sedation with a combination of ketamine with a dose of 0.3mg/kg every five minutes. and propofol at a dose of 2 mg/kg every five minutes.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Appropriate sedation during surgery with monitoring of vital signs during surgery. Timepoint: 0, 10, 20, 30, 40, 60 minutes in the operating room and 0, 15, 30 minutes in recovery. Method of measurement: monitoring device.</prim_outcome>
      <prim_outcome>Pain intensity during and after surgery. Timepoint: During recovery and during surgery. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Consent of the surgeon and the patient. Timepoint: During recovery and during surgery. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Drug's side effect. Timepoint: in recovery room , after being alert. Method of measurement: questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>isfahan university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-27</approval_date>
        <contact_name>ethics committee of isfehan university of medical science</contact_name>
        <contact_address>feiz hospital isfehan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
